{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:24:32Z","timestamp":1787156672930,"version":"build-2736575974"},"reference-count":128,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100020951","name":"Fonds de recherche du Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtha.2026.06.017","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:40:25Z","timestamp":1782492025000},"page":"3102-3115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The evolving role of heparin in sepsis: therapeutic potential in the age of immunothrombosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-1393","authenticated-orcid":false,"given":"Patricia C.","family":"Liaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zarychanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain A.","family":"Lother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher A.","family":"Mendelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.06.017_bib1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.06.017_bib2","unstructured":"Monti G, Landoni G, Taddeo D, Isella F, Zangrillo A. Clinical aspects of sepsis: an overview. In: Mancini, N, editor, Sepsis. Methods in molecular biology, vol 1237. Humana Press, New York, NY."},{"key":"10.1016\/j.jtha.2026.06.017_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40560-019-0383-3","article-title":"Variations in infection sites and mortality rates among patients in intensive care units with severe sepsis and septic shock in Japan","volume":"7","author":"Abe","year":"2019","journal-title":"J Intensive Care"},{"key":"10.1016\/j.jtha.2026.06.017_bib4","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012","volume":"39","author":"Dellinger","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMp1707170","article-title":"Recognizing sepsis as a global health priority \u2013 a WHO resolution","volume":"377","author":"Reinhart","year":"2017","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.06.017_bib8","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1001\/jama.2010.1553","article-title":"Long-term cognitive impairment and functional disability among survivors of severe sepsis","volume":"304","author":"Iwashyna","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.06.017_bib9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00134-021-06479-y","article-title":"Association between sepsis survivorship and long-term cardiovascular outcomes in adults: a systematic review and meta-analysis","volume":"47","author":"Kosyakovsky","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","article-title":"Why have clinical trials in sepsis failed?","volume":"20","author":"Marshall","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/17512433.2019.1643235","article-title":"Clinical trial design for unmet clinical needs: a spotlight on sepsis","volume":"12","author":"Vincent","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.06.017_bib12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41591-022-01843-x","article-title":"Redefining critical illness","volume":"28","author":"Maslove","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib13","first-page":"35","volume":"13","author":"Husak","year":"2010"},{"key":"10.1016\/j.jtha.2026.06.017_bib14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/CCM.0b013e31827c09f8","article-title":"Benchmarking the incidence and mortality of severe sepsis in the United States","volume":"41","author":"Gaieski","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.11-0352","article-title":"Nationwide trends of severe sepsis in the 21st century (2000-2007)","volume":"140","author":"Kumar","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.06.017_bib16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1055\/s-0035-1556730","article-title":"Coagulopathy of acute sepsis","volume":"41","author":"Semeraro","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib17","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1378\/chest.15-0287","article-title":"VTE incidence and risk factors in patients with severe sepsis and septic shock","volume":"148","author":"Kaplan","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.06.017_bib18","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa1014475","article-title":"Dalteparin versus unfractionated heparin in critically ill patients","volume":"364","author":"Cook","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.thromres.2019.04.025","article-title":"Role of disseminated intravascular coagulation in severe sepsis","volume":"178","author":"Gando","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.06.017_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/cc12783","article-title":"A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis","volume":"17","author":"Gando","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.jtha.2026.06.017_bib21","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/jth.14973","article-title":"Identification of hemostatic markers that define the pre-DIC state: a multi-center observational study","volume":"18","author":"Jackson Chornenki","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib22","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1378\/chest.12-2112","article-title":"Trends in the incidence and outcomes of disseminated intravascular coagulation in critically Ill patients (2004-2010): a population-based study","volume":"143","author":"Singh","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.06.017_bib23","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.jtha.2025.03.038","article-title":"Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation","volume":"23","author":"Iba","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.37","article-title":"Disseminated intravascular coagulation","volume":"2","author":"Gando","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2026.06.017_bib25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Bruhl","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib26","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jtha.2026.06.017_bib27","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.arcmed.2021.07.003","article-title":"Roles of coagulation abnormalities and microthrombosis in sepsis: pathophysiology, diagnosis, and treatment","volume":"52","author":"Iba","year":"2021","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jtha.2026.06.017_bib28","doi-asserted-by":"crossref","first-page":"E1156","DOI":"10.1503\/cmaj.201240","article-title":"Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19","volume":"192","author":"Godoy","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.jtha.2026.06.017_bib29","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3389\/fimmu.2020.01962","article-title":"Crosstalk between platelets and microbial pathogens","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2026.06.017_bib30","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/rth2.12406","article-title":"Antiviral anticoagulation","volume":"4","author":"Pryzdial","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-020-00954-7","article-title":"SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2026.06.017_bib32","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1111\/jth.12977","article-title":"Extracellular DNA and histones: double-edged swords in immunothrombosis","volume":"13","author":"Gould","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib33","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm.2184","article-title":"Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases","volume":"16","author":"Massberg","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib34","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1111\/jth.15873","article-title":"Mechanisms of ADAMTS13 regulation","volume":"20","author":"DeYoung","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib35","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1111\/j.1538-7836.2011.04465.x","article-title":"Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus","volume":"9","author":"Swystun","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib36","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/ATVBAHA.114.304114","article-title":"Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms","volume":"34","author":"Gould","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2026.06.017_bib37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/SHK.0000000000000397","article-title":"Comparison of the proinflammatory and procoagulant properties of nuclear, mitochondrial, and bacterial DNA","volume":"44","author":"Bhagirath","year":"2015","journal-title":"Shock"},{"key":"10.1016\/j.jtha.2026.06.017_bib38","first-page":"2524","article-title":"Comparison of the source and prognostic utility of cfDNA in trauma and sepsis","volume":"18","author":"Chornenki","year":"2020","journal-title":"Intensive Care Med Exp"},{"key":"10.1016\/j.jtha.2026.06.017_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/cc11466","article-title":"Prognostic utility and characterization of cell-free DNA in patients with severe sepsis","volume":"16","author":"Dwivedi","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.jtha.2026.06.017_bib40","article-title":"Mortality risk profiles for sepsis: a novel longitudinal and multivariable approach","volume":"1","author":"Liaw","year":"2019","journal-title":"Crit Care Explor"},{"key":"10.1016\/j.jtha.2026.06.017_bib41","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1161\/ATVBAHA.115.306035","article-title":"Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis","volume":"35","author":"Gould","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2026.06.017_bib42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.blre.2015.12.004","article-title":"DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC","volume":"30","author":"Liaw","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2026.06.017_bib43","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1002\/eji.201243224","article-title":"Histones trigger sterile inflammation by activating the NLRP3 inflammasome","volume":"43","author":"Allam","year":"2013","journal-title":"EurJ Immunol"},{"key":"10.1016\/j.jtha.2026.06.017_bib44","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.2053","article-title":"Extracellular histones are major mediators of death in sepsis","volume":"15","author":"Xu","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib45","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/jth.15706","article-title":"Investigations of the effectiveness of heparin variants as inhibitors of histones","volume":"20","author":"Sharma","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1164\/rccm.201206-1037OC","article-title":"Circulating histones are mediators of trauma-associated lung injury","volume":"187","author":"Abrams","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib47","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/SHK.0000000000000680","article-title":"Extracellular histones increase tissue factor activity and enhance thrombin generation by human blood monocytes","volume":"46","author":"Gould","year":"2016","journal-title":"Shock"},{"key":"10.1016\/j.jtha.2026.06.017_bib48","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/jth.12677","article-title":"Histones induce phosphatidylserine exposure and a procoagulant phenotype in human red blood cells","volume":"12","author":"Semeraro","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib49","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/jth.13493","article-title":"Histones link inflammation and thrombosis through the induction of Weibel\u2013Palade body exocytosis","volume":"14","author":"Michels","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib50","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.4049\/jimmunol.1203181","article-title":"Human CRP defends against the toxicity of circulating histones","volume":"191","author":"Abrams","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jtha.2026.06.017_bib51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.CIR.0000140901.04538.ae","article-title":"New anticoagulants for treatment of venous thromboembolism","volume":"110","author":"Weitz","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.06.017_bib52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0006-291X(76)90558-1","article-title":"The separation of active and inactive forms of heparin","volume":"69","author":"Lam","year":"1976","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jtha.2026.06.017_bib53","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1055\/s-0040-1715460","article-title":"The anticoagulant and nonanticoagulant properties of heparin","volume":"120","author":"Beurskens","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib54","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.imbio.2014.06.005","article-title":"Unfractionated heparin suppresses lipopolysaccharide-induced monocyte chemoattractant protein-1 expression in human microvascular endothelial cells by blocking Kr\u00fcppel-like factor 5 and nuclear factor-\u03baB pathway","volume":"219","author":"Li","year":"2014","journal-title":"Immunobiology"},{"key":"10.1016\/j.jtha.2026.06.017_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233644","article-title":"Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood","volume":"15","author":"Hogwood","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2026.06.017_bib56","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2021.01.007","article-title":"Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties","volume":"54","author":"Tang","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jtha.2026.06.017_bib57","doi-asserted-by":"crossref","first-page":"13090","DOI":"10.1016\/S0021-9258(18)37675-0","article-title":"Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro","volume":"263","author":"Linhardt","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2026.06.017_bib58","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.4049\/jimmunol.148.10.3210","article-title":"Heparin and modified heparin inhibit complement activation in vivo","volume":"148","author":"Weiler","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.jtha.2026.06.017_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40635-015-0072-z","article-title":"Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction","volume":"3","author":"Iba","year":"2015","journal-title":"Intensive Care Med Exp"},{"key":"10.1016\/j.jtha.2026.06.017_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.984835","article-title":"A potential new pathway for heparin treatment of sepsis-induced lung injury: inhibition of pulmonary endothelial cell pyroptosis by blocking hMGB1-LPS-induced caspase-11 activation","volume":"12","author":"Yang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jtha.2026.06.017_bib61","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin","volume":"120","author":"Mycroft-West","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101507","article-title":"The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms","volume":"298","author":"Paiardi","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2026.06.017_bib63","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/SHK.0000000000001804","article-title":"Mechanistic studies of DNase I activity: impact of heparin variants and PAD4","volume":"56","author":"Sohrabipour","year":"2021","journal-title":"Shock"},{"key":"10.1016\/j.jtha.2026.06.017_bib64","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/SHK.0000000000002165","article-title":"Investigation of the pathological effects of histones, DNA, and nucleosomes in a murine model of sepsis","volume":"60","author":"Medeiros","year":"2023","journal-title":"Shock"},{"key":"10.1016\/j.jtha.2026.06.017_bib65","article-title":"Heparin attenuates histone-mediated cytotoxicity in septic acute kidney injury","volume":"7","author":"Wang","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2026.06.017_bib66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12950-025-00437-x","article-title":"Unfractionated heparin attenuated histone-induced pulmonary endothelial glycocalyx injury through Ang\/Tie2 pathway","volume":"22","author":"Yin","year":"2025","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.jtha.2026.06.017_bib67","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1021\/acs.biomac.5c01085","article-title":"Simultaneous removal of endotoxin and circulating histones by heparin-grafted chitosan-cellulose composite microspheres for multitargeted hemoperfusion in septic blood","volume":"26","author":"Cheng","year":"2025","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jtha.2026.06.017_bib68","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40635-025-00790-4","article-title":"A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients","volume":"13","author":"Van Mourik","year":"2025","journal-title":"Intensive Care Med Exp"},{"key":"10.1016\/j.jtha.2026.06.017_bib69","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/j.jtha.2025.03.039","article-title":"Proteolytic neutralization of extracellular histones by neutrophil elastase is enhanced by heparin","volume":"23","author":"Huckriede","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib70","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200303RR","article-title":"Mechanisms of pulmonary endothelial permeability and inflammation caused by extracellular histone subunits H3 and H4","volume":"36","author":"Ramasubramanian","year":"2022","journal-title":"FASEB J"},{"key":"10.1016\/j.jtha.2026.06.017_bib71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.molimm.2021.04.002","article-title":"Extracellular histones aggravate inflammation in ARDS by promoting alveolar macrophage pyroptosis","volume":"135","author":"Jiang","year":"2021","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jtha.2026.06.017_bib72","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/ijms23031823","article-title":"Heparin-functionalized adsorbents eliminate central effectors of immunothrombosis, including platelet factor 4, high-mobility group box 1 protein and histones","volume":"23","author":"Kuijpers","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2026.06.017_bib73","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2209528120","article-title":"Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis","volume":"120","author":"Liao","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2026.06.017_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115412","article-title":"Non-anticoagulant heparin alleviates myocardial ischemia-reperfusion injury through inhibiting GSDMD-mediated cardiomyocyte pyroptosis via the HMGB1\/RAGE pathway","volume":"165","author":"Wang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jtha.2026.06.017_bib75","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1165\/rcmb.2016-0069OC","article-title":"2-O, 3-O Desulfated heparin blocks high mobility group box 1 release by inhibition of p300 acetyltransferase activity","volume":"56","author":"Zheng","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jtha.2026.06.017_bib76","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3390\/polym14122470","article-title":"Heparin protects severe acute pancreatitis by Inhibiting HMGB-1 active secretion from macrophages","volume":"14","author":"Yang","year":"2022","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.jtha.2026.06.017_bib77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/biom12010101","article-title":"HMGB1 inhibition to ameliorate organ failure and increase survival in trauma","volume":"12","author":"Yang","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jtha.2026.06.017_bib78","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.intimp.2010.11.014","article-title":"Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro","volume":"11","author":"Ling","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jtha.2026.06.017_bib79","first-page":"203","article-title":"Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin\u2019s effect on binding","volume":"63","author":"Liua","year":"2009","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.jtha.2026.06.017_bib80","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1074\/jbc.M102950200","article-title":"The S100 family heterodimer, MRP-8\/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells","volume":"277","author":"Robinson","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2026.06.017_bib81","first-page":"50","article-title":"Low molecular weight heparin prevents CLP-induced acute lung injury in rats by anti-inflammatory coagulation","volume":"13","author":"Lu","year":"2013","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.jtha.2026.06.017_bib82","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.gene.2014.12.018","article-title":"Low molecular weight heparin may prevent acute lung injury induced by sepsis in rats","volume":"557","author":"Ning","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.jtha.2026.06.017_bib83","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/SHK.0000000000002095","article-title":"The effects of DNase I and low-molecular-weight heparin in a murine model of polymicrobial abdominal sepsis","volume":"59","author":"Medeiros","year":"2023","journal-title":"Shock"},{"key":"10.1016\/j.jtha.2026.06.017_bib84","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1160\/TH07-01-0006","article-title":"The role of heparin and allied compounds in the treatment of sepsis","volume":"98","author":"Cornet","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib85","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/SHK.0000000000002566","article-title":"Heparin and DNase I treat myocardial injury in septic mice","volume":"63","author":"Wang","year":"2025","journal-title":"Shock"},{"key":"10.1016\/j.jtha.2026.06.017_bib86","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/CCM.0b013e31820eb718","article-title":"The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies","volume":"39","author":"Li","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib87","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2013-07-514984","article-title":"Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis","volume":"123","author":"Wildhagen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.017_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40635-020-00366-4","article-title":"National Preclinical Sepsis Platform: developing a framework for accelerating innovation in Canadian sepsis research","volume":"9","author":"Mendelson","year":"2021","journal-title":"Intensive Care Med Exp"},{"key":"10.1016\/j.jtha.2026.06.017_bib89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40635-023-00533-3","article-title":"Development and characterization of a fecal-induced peritonitis model of murine sepsis: results from a multi-laboratory study and iterative modification of experimental conditions","volume":"11","author":"Sharma","year":"2023","journal-title":"Intensive Care Med Exp"},{"key":"10.1016\/j.jtha.2026.06.017_bib90","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1097\/CCM.0b013e31818b8c6b","article-title":"Early intravenous unfractionated heparin and mortality in septic shock","volume":"36","author":"Zarychanski","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib91","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/00006454-199410000-00004","article-title":"The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans","volume":"3","author":"Kuppermann","year":"1994","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jtha.2026.06.017_bib92","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib93","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(04)16259-4","article-title":"Drug intervention trials in sepsis: divergent results","volume":"363","author":"Polderman","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.06.017_bib94","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S2213-2600(23)00237-0","article-title":"Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials","volume":"11","author":"Sinha","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib95","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CCM.0000000000000763","article-title":"The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis","volume":"43","author":"Zarychanski","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib96","article-title":"Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials","volume":"6","author":"Fan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2026.06.017_bib97","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with Covid-19","volume":"385","author":"Goligher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib98","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib99","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1136\/bmj.n2400","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with Covid-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2026.06.017_bib100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7326\/ANNALS-24-00800","article-title":"Anticoagulation among patients hospitalized for COVID-19 : a systematic review and prospective meta-analysis","volume":"178","author":"Vale","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib101","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial","volume":"326","author":"Connors","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.06.017_bib102","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.2022.2910","article-title":"Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"327","author":"Bradbury","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.06.017_bib103","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nri.2017.105","article-title":"Neutrophil extracellular traps in immunity and disease","volume":"18","author":"Papayannopoulos","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtha.2026.06.017_bib104","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2017.36","article-title":"The immunopathology of sepsis and potential therapeutic targets","volume":"17","author":"van der","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtha.2026.06.017_bib105","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/jth.14975","article-title":"Coagulopathy in COVID-19","volume":"18","author":"Iba","year":"2020","journal-title":"J Thromb Haemos"},{"key":"10.1016\/j.jtha.2026.06.017_bib106","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.06.017_bib107","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib109","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib110","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1538-7836.2011.04432.x","article-title":"Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents","volume":"9","author":"Levi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib111","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.210637","article-title":"Heparin-induced thrombocytopenia","volume":"193","author":"Jevtic","year":"2021","journal-title":"CMAJ"},{"key":"10.1016\/j.jtha.2026.06.017_bib112","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.017_bib113","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1378\/chest.13-0057","article-title":"Heparin-induced thrombocytopenia in medical surgical critical illness","volume":"144","author":"Warkentin","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.06.017_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10040683","article-title":"Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management","volume":"10","author":"Marchetti","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib115","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-015-1880-5","article-title":"A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency","volume":"71","author":"Atiq","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.06.017_bib116","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib117","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1055\/s-0040-1719083","article-title":"Monitoring of unfractionated heparin in severe COVID-19: an observational study of patients on CRRT and ECMO","volume":"4","author":"Streng","year":"2020","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2026.06.017_bib118","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11239-024-03048-0","article-title":"Bleeding outcomes in critically ill patients on heparin with discordant aPTT and anti-Xa activity","volume":"58","author":"Halawi","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2026.06.017_bib119","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.06.017_bib120","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDra2200322","article-title":"Perioperative management of anticoagulant and antiplatelet therapy","volume":"2","author":"Douketis","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jtha.2026.06.017_bib121","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Th\u00e9roux","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.06.017_bib122","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.amjcard.2007.04.057","article-title":"Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE Trial)","volume":"100","author":"Valencia","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2026.06.017_bib123","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/CIRCINTERVENTIONS.111.961912","article-title":"Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry","volume":"4","author":"Bangalore","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jtha.2026.06.017_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbplus.2022.100121","article-title":"Alterations in heparan sulfate proteoglycan synthesis and sulfation and the impact on vascular endothelial function","volume":"16","author":"Pretorius","year":"2022","journal-title":"Matrix Biol Plus"},{"key":"10.1016\/j.jtha.2026.06.017_bib126","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/jth.14642","article-title":"Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis","volume":"18","author":"Keshari","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.017_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100780","article-title":"Heparin dose intensity and organ support-free days in patients hospitalized for COVID-19","volume":"3","author":"Godoy","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.jtha.2026.06.017_bib128","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jama.2023.3651","article-title":"Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19","volume":"329","author":"Goligher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.06.017_bib129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s44231-024-00070-x","article-title":"Heparin therapy and mortality in patients with sepsis: an observational study using a marginal structural cox model based on MIMIC-IV database","volume":"4","author":"Jiang","year":"2024","journal-title":"Intensive Care Research"},{"key":"10.1016\/j.jtha.2026.06.017_bib130","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/ATVBAHA.124.321108","article-title":"On-treatment change in d-dimer is associated with differential outcomes among therapeutic dose heparin-treated noncritically ill patients hospitalized for COVID-19","volume":"45","author":"Wahid","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626004022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626004022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:28:17Z","timestamp":1787153297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626004022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":128,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1538783626004022"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.06.017","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving role of heparin in sepsis: therapeutic potential in the age of immunothrombosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}